FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Poyurovsky

Research Profile

Disorders

Chemicals & Drugs

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Geographic Areas

Israel

Procedures

Co-author Network

Publications

TOP 3
Michael Poyurovsky; Camil Fuchs; Aya Levi; Artashez Pashinian; Ronit Weizman; Abraham Weizman
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Roee Admon; Maya Bleich-Cohen; Sarit Faragian; Michael Poyurovsky; Ronit Weizmant; Talma Hendler
Functional and structural neural indices of risk aversion in obsessive-compulsive disorder (OCD).
Michael Poyurovsky; Rajiv Tandon; Ira Glick; Lorrin M Koran; Ronit Weizman; Joseph Zohar; Abraham Weizman
Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Poyurovsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael Poyurovsky; Camil Fuchs; Aya Levi; Artashez Pashinian; Ronit Weizman; Abraham Weizman
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Psychopharmacology 2013;226(3):615-22.
2012: Roee Admon; Maya Bleich-Cohen; Sarit Faragian; Michael Poyurovsky; Ronit Weizmant; Talma Hendler
Functional and structural neural indices of risk aversion in obsessive-compulsive disorder (OCD).
Psychiatry research 2012;203(2-3):207-13.
2012: Michael Poyurovsky; Rajiv Tandon; Ira Glick; Lorrin M Koran; Ronit Weizman; Joseph Zohar; Abraham Weizman
Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications.
Comprehensive psychiatry 2012;53(5):480-3.
2012: Sarit Faragian; Camil Fuchs; Artashez Pashinian; Abraham Weizman; Ronit Weizman; Michael Poyurovsky
Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder.
Psychiatry research 2012;197(1-2):19-22.
2012: Maya Bleich-Cohen; Sarit Faragian; Michael Poyurovsky; Haggai Sharon; Ronit Weizman; Talma Hendler
Diminished language lateralization in schizophrenia corresponds to impaired inter-hemispheric functional connectivity.
Schizophrenia research 2012;134(2-3):131-6.
2012: Jaime Kulisevsky; Michael Poyurovsky
Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
European neurology 2012;67(1):4-11.
2011: Roy Salomon; Ronit Weizman; Michael Poyurovsky; Maya Bleich-Cohen; Ilan Dinstien; Avital Hahamy-Dubossarsky; Talma Hendler; Moshe Kotler; Marina Kupchik; Rafael Malach
Global functional connectivity deficits in schizophrenia depend on behavioral state.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2011;31(36):12972-81.
2011: Vered Baloush-Kleinman; Stephen Z Levine; David Roe; Dan Shnitt; Abraham Weizman; Michael Poyurovsky
Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Schizophrenia research 2011;130(1-3):176-81.
2011: Michael Poyurovsky; Ronit Weizman; Abraham Weizman
Mirtazapine - a multifunctional drug: low dose for akathisia.
CNS spectrums 2011;16(2):63.
2010: Michael Poyurovsky; I Glick; L M Koran
Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms.
Journal of psychopharmacology (Oxford, England) 2010;24(6):861-6.
2010: Michael Poyurovsky
Acute antipsychotic-induced akathisia revisited.
The British journal of psychiatry : the journal of mental science 2010;196(2):89-91.
2009: Sarit Faragian; Artashez Pashinian; Camil Fuchs; Michael Poyurovsky
Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder.
Progress in neuro-psychopharmacology & biological psychiatry 2009;33(6):1009-12.
2009: Michael Poyurovsky; Sarit Faragian; Camil Fuchs; Artashez Pashinian
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
The Israel journal of psychiatry and related sciences 2009;46(3):213-20.
2008: Ira D Glick; Michael Poyurovsky; Oxana Ivanova; Lorrin M Koran
Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
The Journal of clinical psychiatry 2008;69(12):1856-9.
2008: Michael Poyurovsky; Sarit Faragian; Adeeb Shabeta; Anatoly Kosov
Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder.
Psychiatry research 2008;159(1-2):133-9.
2008: Michael Poyurovsky; Sarit Faragian; Artashez Pashinian; Lilah Heidrach; Camil Fuchs; Ronit Weizman; Lorrin Koran
Clinical characteristics of schizotypal-related obsessive-compulsive disorder.
Psychiatry research 2008;159(1-2):254-8.
2008: Michael Poyurovsky; Ronit Weizman; Abraham Weizman
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
The American journal of psychiatry 2008;165(3):398; author reply 398-9.
2008: Sarit Faragian; Rena Kurs; Michael Poyurovsky
Insight into obsessive-compulsive symptoms and awareness of illness in adolescent schizophrenia patients with and without OCD.
Child psychiatry and human development 2008;39(1):39-48.
2008: Michael Poyurovsky
Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder.
The Israel journal of psychiatry and related sciences 2008;45(3):219-20.
2007: Michael Poyurovsky; Sarit Faragian; Vered Kleinman-Balush; Artashez Pashinian; Rena Kurs; Camil Fuchs
Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder.
The Journal of nervous and mental disease 2007;195(9):765-8.
2007: Michael Poyurovsky; Camil Fuchs; Artashez Pashinian; Aya Levi; Sarit Faragian; Rachel Maayan; Irit Gil-Ad
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Psychopharmacology 2007;192(3):441-8.
2007: Michael Poyurovsky; Sarit Faragian; Artashez Pashinian; Aya Levi; Alexander Viosburd; Rafael Stryjer; Ronit Weizman; Camil Fuchs; Abraham Weizman
Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder.
The Journal of neuropsychiatry and clinical neurosciences 2007;19(2):145-50.
2006: Michael Poyurovsky; Camil Fuchs; Sarit Faragian; Victoria Kriss; Gregory Weisman; Artashez Pashinian; Ronit Weizman; Abraham Weizman
Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2006;51(12):746-54.
2006: Artashez Pashinian; Sarit Faragian; Aya Levi; Maruke Yeghiyan; Khachatur Gasparyan; Ronit Weizman; Abraham Weizman; Camil Fuchs; Michael Poyurovsky
Obsessive-compulsive disorder in bipolar disorder patients with first manic episode.
Journal of affective disorders 2006;94(1-3):151-6.
2006: Michael Poyurovsky; Artashez Pashinian; Ronit Weizman; Camil Fuchs; Abraham Weizman
Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.
Biological psychiatry 2006;59(11):1071-7.
2006: Michael Poyurovsky; Josef Bergman; Ronit Weizman
Obsessive-compulsive disorder in elderly schizophrenia patients.
Journal of psychiatric research 2006;40(3):189-91.
2005: Michael Poyurovsky; Elena Michaelovsky; Amos Frisch; Gabriela Knoll; Ilan Amir; Boris Finkel; Feodor Buniak; Haggai Hermesh; Ronit Weizman
COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study.
Neuroscience letters 2005;389(1):21-4.
2005: Michael Poyurovsky; Ronit Weizman; Abraham Weizman; Lorrin M Koran
Memantine for treatment-resistant OCD.
The American journal of psychiatry 2005;162(11):2191-2.
2005: Michael Poyurovsky; L M Koran
Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications.
Journal of psychiatric research 2005;39(4):399-408.
2005: Danny Koren; Michael Poyurovsky; Larry J Seidman; Morris Goldsmith; Sigal Wenger; Ehud M Klein
The neuropsychological basis of competence to consent in first-episode schizophrenia: a pilot metacognitive study.
Biological psychiatry 2005;57(6):609-16.
2005: Michael Poyurovsky; Artashez Pashinian; Aya Levi; Ronit Weizman; Abraham Weizman
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
International clinical psychopharmacology 2005;20(2):101-3.
2005: Michael Poyurovsky; Victoria Kriss; Gregory Weisman; Sarit Faragian; Michael Schneidman; Camil Fuchs; Abraham Weizman; Ronit Weizman
Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2005;133B(1):31-6.
2004: Danny Koren; Larry J Seidman; Michael Poyurovsky; Morris Goldsmith; Polina Viksman; Suzi Zichel; Ehud Klein
The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study.
Schizophrenia research 2004;70(2-3):195-202.
2004: Michael Poyurovsky; Vered Tal; Rachel Maayan; Irit Gil-Ad; Camil Fuchs; Abraham Weizman
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2004;14(4):332-6.
2004: Rafael Stryjer; Daniel Grupper; Rael D Strous; Michael Poyurovsky; Abraham Weizman
Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient.
European psychiatry : the journal of the Association of European Psychiatrists 2004;19(4):237-8.
2004: Rachel Maayan; Galit Shaltiel; Michael Poyurovsky; Edward Ramadan; Oren Morad; Allon Nechmad; Abraham Weizman; Galila Agam
Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2004;7(1):71-5.
2004: Michael Poyurovsky; Abraham Weizman; Ronit Weizman
Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.
CNS drugs 2004;18(14):989-1010.
2003: Michael Poyurovsky; Victoria Kriss; Gregory Weisman; Sarit Faragian; Rena Kurs; Michael Schneidman; Camil Fuchs; Abraham Weizman; Ronit Weizman
Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia.
The Journal of clinical psychiatry 2003;64(11):1300-7.
2003: Allon Nechmad; Rachel Maayan; Baruch Spivak; Edward Ramadan; Michael Poyurovsky; Abraham Weizman
Brain neurosteroid changes after paroxetine administration in mice.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2003;13(5):327-32.
2003: Michael Poyurovsky; Svetlana Epshtein; Camil Fuchs; Michael Schneidman; Ronit Weizman; Abraham Weizman
Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study.
Journal of clinical psychopharmacology 2003;23(3):305-8.
2003: Rafael Stryjer; Rael D Strous; Faina Bar; Michael Poyurovsky; Abraham Weizman; Moshe Kotler
Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.
Clinical neuropharmacology 2003;26(3):137-41.
2003: Michael Poyurovsky; Rena Kurs; Abraham Weizman
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
The Journal of clinical psychiatry 2003;64(5):611.
2003: Allon Nechmad; Gideon Ratzoni; Michael Poyurovsky; Sorin Meged; Gideon Avidan; Camil Fuchs; Yuval Bloch; Ronit Weizman
Obsessive-compulsive disorder in adolescent schizophrenia patients.
The American journal of psychiatry 2003;160(5):1002-4.
2003: Michael Poyurovsky; Danny Koren; Inna Gonopolsky; Michael Schneidman; Camil Fuchs; Abraham Weizman; Ronit Weizman
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2003;13(2):123-8.
2003: Michael Poyurovsky; Ilanit Isaacs; Camil Fuchs; Michael Schneidman; Sarit Faragian; Ronit Weizman; Abraham Weizman
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
The American journal of psychiatry 2003;160(2):297-302.
2003: Allon Nechmad; Rachel Maayan; Edward Ramadan; Oren Morad; Michael Poyurovsky; Abraham Weizman
Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2003;13(1):29-31.
2002: Vered Baloush-Kleinman; Michael Poyurovsky; Dany Koren; Michael Schneidman; Abraham Weizman; Dan Shnitt
[Adherence to antipsychotic medication in schizophrenia patients].
Harefuah 2002;141(12):1042-9, 1090.
2002: Michael Poyurovsky; Artashez Pashinian; Irit Gil-Ad; Rachel Maayan; Michael Schneidman; Camil Fuchs; Abraham Weizman
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
The American journal of psychiatry 2002;159(6):1058-60.
2001: Michael Poyurovsky; S Hramenkov; V Isakov; Boris Rauchverger; Ilan Modai; Michael Schneidman; Camil Fuchs; Abraham Weizman
Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia.
Psychiatry research 2001;102(1):49-57.
2000: Michael Poyurovsky; Pnina Dorfman-Etrog; Haggai Hermesh; Hanan Munitz; Gary D Tollefson; Abraham Weizman
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
International clinical psychopharmacology 2000;15(3):169-73.
2000: Amos Frisch; Elena Michaelovsky; Rivka Rockah; Ilan Amir; Haggai Hermesh; Nathaniel Laor; C Fuchs; J Zohar; Bernard Lerer; S F Buniak; S Landa; Michael Poyurovsky; B Shapira; Ronit Weizman
Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2000;10(3):205-9.
2000: Michael Poyurovsky; Rachel Nave; Rachel Epstein; Orna Tzischinsky; Michael Schneidman; Thomas R E Barnes; Abraham Weizman; Peretz Lavie
Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2000;10(3):171-6.
1999: Michael Poyurovsky; Camil Fuchs; Abraham Weizman
Obsessive-compulsive disorder in patients with first-episode schizophrenia.
The American journal of psychiatry 1999;156(12):1998-2000.
1999: Michael Poyurovsky; Abraham Weizman
Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia.
International clinical psychopharmacology 1999;14(6):357-60.
1999: Amos Frisch; D Postilnick; Rivka Rockah; Elena Michaelovsky; S Postilnick; E Birman; Nathaniel Laor; Boris Rauchverger; Anatoly Kreinin; Michael Poyurovsky; Michael Schneidman; Ilan Modai; Ronit Weizman
Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways.
Molecular psychiatry 1999;4(4):389-92.
1999: Michael Poyurovsky; M Shardorodsky; Camil Fuchs; Michael Schneidman; Abraham Weizman
Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
The British journal of psychiatry : the journal of mental science 1999;174():238-42.
1999: Michael Poyurovsky; V Isakov; S Hromnikov; Ilan Modai; B Rauchberger; Michael Schneidman; Abraham Weizman
Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.
International clinical psychopharmacology 1999;14(2):95-100.
1998: Michael Poyurovsky; Y Bergman; D Shoshani; Michael Schneidman; A Weizman
Emergence of obsessive--compulsive symptoms and tics during clozapine withdrawal.
Clinical neuropharmacology 1998;21(2):97-100.
1997: Michael Poyurovsky; Michael Schneidman; A Weizman
Successful treatment of fluoxetine-induced dystonia with low-dose mianserin.
Movement disorders : official journal of the Movement Disorder Society 1997;12(6):1102-5.
1997: Michael Poyurovsky; Abraham Weizman
Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.
International clinical psychopharmacology 1997;12(5):263-8.
1996: Michael Poyurovsky; Ilan Modai; Abraham Weizman
Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis.
International clinical psychopharmacology 1996;11(1):61-3.
1995: Michael Poyurovsky; Anatoly Kreinin; Ilan Modai; Abraham Weizman
Lithium-induced akathisia responds to low-dose mianserin: case report.
International clinical psychopharmacology 1995;10(4):261-3.
1995: Michael Poyurovsky; A Kosov; E Halperin; D Enoch; Michael Schneidman; Abraham Weizman
Akathisia-like behavior following ECT, and its successful treatment with low-dose mianserin.
International clinical psychopharmacology 1995;10(4):257-60.
1995: Michael Poyurovsky; E Halperin; D Enoch; M Shneidman; Abraham Weizman
Fluvoxamine treatment of compulsivity, impulsivity, and aggression.
The American journal of psychiatry 1995;152(11):1688-9.